-5.12%
-0.07%
-11.26%
-13.07%
-11.57%
-27.02%
-17.00%
AI Spotlight on DXR
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Market Data
| Last Price | 7.68 |
| Change Percentage | -5.12% |
| Open | 7.98 |
| Previous Close | 8.1 |
| Market Cap ( Millions) | 37 |
| Volume | 5004 |
| Year High | 10 |
| Year Low | 7.19 |
| M A 50 | 8.49 |
| M A 200 | 8.96 |
Financial Ratios
| FCF Yield | -12.60% |
| Dividend Yield | 0.00% |
| ROE | 5.10% |
| Debt / Equity | 5.05% |
| Net Debt / EBIDTA | -52.08% |
| Price To Book | 1.14 |
| Price Earnings Ratio | 22.0 |
| Price To FCF | -7.94 |
| Price To sales | 241.06 |
| EV / EBITDA | -12.26 |
News
- Dec -18 - Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
- Oct -09 - DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
- Oct -08 - Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- Sep -27 - Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
- Sep -19 - Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
- Sep -04 - Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
- Sep -03 - Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter
- Sep -03 - Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug -29 - Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network
- Aug -05 - Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide
- Jun -18 - Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting
- Apr -10 - Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
- Mar -26 - Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript
- Mar -25 - Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
- Mar -22 - Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
- Mar -18 - Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
- Mar -18 - Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
- Mar -11 - Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
- Mar -08 - Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
- Feb -26 - Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Investment and Related Activities
Expected Growth : 10.2 %
What the company do ?
Daxor Corporation's Investment and Related Activities segment includes investments in marketable securities, trading securities, and other investments.
Why we expect these perspectives ?
Daxor's Investment and Related Activities segment is poised for growth driven by increasing demand for marketable securities, trading securities, and other investments. The company's strategic investments in diversified portfolios and strong financial position will fuel growth, with a forecast CAGR of 10.2%.
Daxor Corporation Products
| Product Range | What is it ? |
|---|---|
| BVA-100 Blood Volume Analyzer | A diagnostic device that measures blood volume and vascular permeability, helping clinicians to diagnose and monitor various medical conditions such as heart failure, sepsis, and kidney disease. |
| Daxor Blood Volume Analysis Software | A software solution that analyzes data from the BVA-100 to provide accurate and reliable blood volume measurements. |
| Consulting and Training Services | Expert consulting and training services to help healthcare professionals optimize the use of Daxor's products and improve patient care. |
Daxor Corporation's Porter Forces
Threat Of Substitutes
Daxor Corporation faces moderate threat from substitutes, as there are limited alternatives to blood transfusion products, but some hospitals may opt for alternative treatments.
Bargaining Power Of Customers
Daxor Corporation has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.
Bargaining Power Of Suppliers
Daxor Corporation relies on a few key suppliers for raw materials, giving them some bargaining power, but the company's diversified supply chain mitigates this risk.
Threat Of New Entrants
The blood transfusion products market has high barriers to entry, including regulatory hurdles and significant capital requirements, making it difficult for new entrants to join the market.
Intensity Of Rivalry
The blood transfusion products market is highly competitive, with several established players competing for market share, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.17% |
| Debt Cost | 3.95% |
| Equity Weight | 97.83% |
| Equity Cost | 1.68% |
| WACC | 1.73% |
| Leverage | 2.22% |
Daxor Corporation : Quality Control
Daxor Corporation passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SMTI | Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen … |
| WRBY | Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and … |
| LMAT | LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing … |
| RVP | Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and … |
| ATRC | AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
LeMaitre Vascular
A-Score
1-Year Total Return ->
🥈
Daxor
A-Score
1-Year Total Return ->
🥉
Retractable Technologies
A-Score
1-Year Total Return ->
4
Warby Parker
A-Score
1-Year Total Return ->
5
Sanara MedTech
A-Score
1-Year Total Return ->
6
